{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:39Z","timestamp":1792791459684,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\u201cClinician Scientist Research Fellowship\" by the \u00d6GDV, the Austrian Society of Dermatology and Venereology","id":[{"id":"https:\/\/ror.org\/04bstw291","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Amgen Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00879-x","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T05:03:01Z","timestamp":1737003781000},"page":"51-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-0878","authenticated-orcid":false,"given":"Julia Maria","family":"Ressler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1137-7623","authenticated-orcid":false,"given":"Maud","family":"Plaschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2506-9893","authenticated-orcid":false,"given":"Rita","family":"Silmbrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4585-1736","authenticated-orcid":false,"given":"Victoria","family":"Bachmayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2273-7655","authenticated-orcid":false,"given":"Lisa Ellen","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Silly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1014","authenticated-orcid":false,"given":"Nina","family":"Zila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-2610","authenticated-orcid":false,"given":"Anna","family":"Kusienicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-7810","authenticated-orcid":false,"given":"Philipp","family":"Tschandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-3626","authenticated-orcid":false,"given":"Julia","family":"Tittes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Roka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Haslik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7080-5259","authenticated-orcid":false,"given":"Peter","family":"Petzelbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Kunstfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0698-2992","authenticated-orcid":false,"given":"Matthias","family":"Farlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-4784","authenticated-orcid":false,"given":"Florian","family":"Halbritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-0227","authenticated-orcid":false,"given":"Christoph","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"879_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjd.15321","volume":"177","author":"JAC Verkouteren","year":"2017","unstructured":"Verkouteren, J. A. C., Ramdas, K. H. R., Wakkee, M. & Nijsten, T. Epidemiology of basal cell carcinoma: scholarly review. Br. J. Dermatol. 177, 359\u2013372 (2017).","journal-title":"Br. J. Dermatol."},{"key":"879_CR2","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/bjd.20964","volume":"186","author":"J Kappelin","year":"2022","unstructured":"Kappelin, J., Green, A. C., Ingvar, \u00c5., Ahnlide, I. & Nielsen, K. Incidence and trends of basal cell carcinoma in Sweden: a population-based registry study. Br. J. Dermatol. 186, 963\u2013969 (2022).","journal-title":"Br. J. Dermatol."},{"key":"879_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","volume":"166","author":"A Lomas","year":"2012","unstructured":"Lomas, A., Leonardi-Bee, J. & Bath-Hextall, F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br. J. Dermatol. 166, 1069\u20131080 (2012).","journal-title":"Br. J. Dermatol."},{"key":"879_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/bjd.20871","volume":"186","author":"K Schreuder","year":"2022","unstructured":"Schreuder, K., Hollestein, L., Nijsten, T. E. C., Wakkee, M. & Louwman, M. W. J. A nationwide study of the incidence and trends of first and multiple basal cell carcinomas in the Netherlands and prediction of future incidence. Br. J. Dermatol. 186, 476\u2013484 (2022).","journal-title":"Br. J. Dermatol."},{"key":"879_CR5","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s00432-022-04207-7","volume":"49","author":"M El-Khalawany","year":"2023","unstructured":"El-Khalawany, M. et al. Epidemiological and clinicopathological analysis of basal cell carcinoma in Egyptian population: a 5-year retrospective multicenter study. J. Cancer Res. Clin. Oncol. 49, 3121\u20133129 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"879_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","volume":"118","author":"K Peris","year":"2019","unstructured":"Peris, K. et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur. J. Cancer 118, 10\u201334 (2019).","journal-title":"Eur. J. Cancer"},{"key":"879_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.5114\/pdia.2014.40959","volume":"31","author":"MP Szewczyk","year":"2014","unstructured":"Szewczyk, M. P. et al. Analysis of selected recurrence risk factors after treatment of head and neck basal cell carcinoma. Postepy. Dermatol. Alergol. 31, 146\u2013151 (2014).","journal-title":"Postepy. Dermatol. Alergol."},{"key":"879_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jaad.2019.09.075","volume":"83","author":"FC Morgan","year":"2020","unstructured":"Morgan, F. C. et al. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2\u2009cm or larger in diameter. J. Am. Acad. Dermatol. 83, 832\u2013838 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"879_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1590\/abd1806-4841.20198298","volume":"94","author":"RN Kondo","year":"2019","unstructured":"Kondo, R. N., Gon, A. D. S. & Pontello Junior, R. Recurrence rate of basal cell carcinoma in patients submitted to skin flaps or grafts. An. Bras. Dermatol. 94, 442\u2013445 (2019).","journal-title":"An. Bras. Dermatol."},{"key":"879_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/medicina56020066","volume":"56","author":"L R\u0103ducu","year":"2020","unstructured":"R\u0103ducu, L. et al. Quality of life in patients with surgically removed skin tumors. Medicina 56, 66 (2020).","journal-title":"Medicina"},{"key":"879_CR11","doi-asserted-by":"publisher","first-page":"100844","DOI":"10.1016\/j.eclinm.2021.100844","volume":"35","author":"N Bertrand","year":"2021","unstructured":"Bertrand, N. et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma. EClinicalMedicine 35, 100844 (2021).","journal-title":"EClinicalMedicine"},{"key":"879_CR12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bjd.18552","volume":"182","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br. J. Dermatol. 182, 1369\u20131378 (2020).","journal-title":"Br. J. Dermatol."},{"key":"879_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/jid.2013.276","volume":"134","author":"SS Jayaraman","year":"2014","unstructured":"Jayaraman, S. S., Rayhan, D. J., Hazany, S. & Kolodney, M. S. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J. Invest. Dermatol. 134, 213\u2013220 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"879_CR14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/cup.14381","volume":"50","author":"JM Ressler","year":"2023","unstructured":"Ressler, J. M. et al. Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T-cells. J. Cutan. Pathol. 50, 544\u2013551 (2023).","journal-title":"J. Cutan. Pathol."},{"key":"879_CR15","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"879_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2051-1426-2-11","volume":"2","author":"HL Kaufman","year":"2014","unstructured":"Kaufman, H. L., Ruby, C. E., Hughes, T. & Slingluff, C. L. Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J. Immunother. Cancer 2, 11 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"879_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119.e10 (2017).","journal-title":"Cell"},{"key":"879_CR18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","volume":"27","author":"R Dummer","year":"2021","unstructured":"Dummer, R. et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat. Med. 27, 1789\u20131796 (2021).","journal-title":"Nat. Med."},{"key":"879_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","volume":"17","author":"HL Kaufman","year":"2010","unstructured":"Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718\u2013730 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"879_CR20","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1111\/jdv.16922","volume":"35","author":"G Richtig","year":"2021","unstructured":"Richtig, G. et al. Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions - a case series. J. Eur. Acad. Dermatol. Venereol. 35, e209\u2013e211 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"879_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301\u2013309 (2021).","journal-title":"Nat. Med."},{"key":"879_CR22","first-page":"100384","volume":"3","author":"S Rosner","year":"2022","unstructured":"Rosner, S., Liu, C., Forde, P. M. & Hu, C. Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC: a meta-analysis. JTO Clin. Res. Rep. 3, 100384 (2022).","journal-title":"JTO Clin. Res. Rep."},{"key":"879_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12890-022-02110-y","volume":"22","author":"X Qiu","year":"2022","unstructured":"Qiu, X. et al. Identification of HMGB2 associated with proliferation, invasion and prognosis in lung adenocarcinoma via weighted gene co-expression network analysis. BMC Pulm. Med. 22, 310 (2022).","journal-title":"BMC Pulm. Med."},{"key":"879_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775\u2013789.e18 (2019).","journal-title":"Cell"},{"key":"879_CR25","doi-asserted-by":"publisher","first-page":"1746573","DOI":"10.1080\/2162402X.2020.1746573","volume":"9","author":"F Liu","year":"2020","unstructured":"Liu, F. et al. Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma. Oncoimmunology 9, 1746573 (2020).","journal-title":"Oncoimmunology"},{"key":"879_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"879_CR27","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1093\/bioinformatics\/btx286","volume":"33","author":"N Tickotsky","year":"2017","unstructured":"Tickotsky, N., Sagiv, T., Prilusky, J., Shifrut, E. & Friedman, N. McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences. Bioinformatics 33, 2924\u20132929 (2017).","journal-title":"Bioinformatics"},{"key":"879_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene Ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet 25, 25\u201329 (2000).","journal-title":"Nat. Genet"},{"key":"879_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442\u2013459.e29 (2020).","journal-title":"Cell"},{"key":"879_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma, R. Y., Black, A. & Qian, B. Z. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 43, 546\u2013563 (2022).","journal-title":"Trends Immunol"},{"key":"879_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16, 7\u201319 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"879_CR32","doi-asserted-by":"publisher","first-page":"954936","DOI":"10.3389\/fimmu.2022.954936","volume":"13","author":"I Rastogi","year":"2022","unstructured":"Rastogi, I. et al. Role of B cells as antigen presenting cells. Front. Immunol. 13, 954936 (2022).","journal-title":"Front. Immunol."},{"key":"879_CR33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri911","volume":"2","author":"JA Trapani","year":"2002","unstructured":"Trapani, J. A. & Smyth, M. J. Functional significance of the perforin\/granzyme cell death pathway. Nat. Rev. Immunol. 2, 735\u2013747 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"879_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/imr.13016","volume":"303","author":"MP Cancro","year":"2021","unstructured":"Cancro, M. P. & Tomayko, M. M. Memory B cells and plasma cells: the differentiative continuum of humoral immunity. Immunol. Rev. 303, 72\u201382 (2021).","journal-title":"Immunol. Rev."},{"key":"879_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/35085509","volume":"412","author":"AM Reimold","year":"2001","unstructured":"Reimold, A. M. et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412, 300\u2013307 (2001).","journal-title":"Nature"},{"key":"879_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","volume":"20","author":"GV Sharonov","year":"2020","unstructured":"Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V. & Chudakov, D. M. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat. Rev. Immunol. 20, 294\u2013307 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"879_CR37","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1016\/j.celrep.2018.05.053","volume":"23","author":"MJ Price","year":"2018","unstructured":"Price, M. J., Patterson, D. G., Scharer, C. D. & Boss, J. M. Progressive upregulation of oxidative metabolism facilitates plasmablast differentiation to a T-independent antigen. Cell Rep. 23, 3152\u20133159 (2018).","journal-title":"Cell Rep."},{"key":"879_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.14336\/AD.2017.0503","volume":"8","author":"S Garcovich","year":"2017","unstructured":"Garcovich, S. et al. Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging Dis. 8, 643\u2013661 (2017).","journal-title":"Aging Dis."},{"key":"879_CR39","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","volume":"71","author":"MS Ally","year":"2014","unstructured":"Ally, M. S. et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J. Am. Acad. Dermatol. 71, 904\u2013911.e1 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"879_CR40","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","volume":"22","author":"AJ Stratigos","year":"2021","unstructured":"Stratigos, A. J. et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 22, 848\u2013857 (2021).","journal-title":"Lancet Oncol."},{"key":"879_CR41","doi-asserted-by":"publisher","first-page":"e001701","DOI":"10.1136\/jitc-2020-001701","volume":"9","author":"JM Ressler","year":"2021","unstructured":"Ressler, J. M. et al. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. J. Immunother. Cancer 9, e001701 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"879_CR42","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers, I. L. M. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat. Med. 28, 1178\u20131188 (2022).","journal-title":"Nat. Med."},{"key":"879_CR43","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.bjps.2017.04.006","volume":"70","author":"LTD Armstrong","year":"2017","unstructured":"Armstrong, L. T. D., Magnusson, M. R. & Guppy, M. P. B. Risk factors for recurrence of facial basal cell carcinoma after surgical excision: a follow-up analysis. J. Plast. Reconstr. Aesthet. Surg. 70, 1738\u20131745 (2017).","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"879_CR44","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/ijd.15065","volume":"59","author":"B Beksa\u00e7","year":"2020","unstructured":"Beksa\u00e7, B. et al. Sparsity of dendritic cells and cytotoxic T cells in tumor microenvironment may lead to recurrence in basal cell carcinoma. Int. J. Dermatol. 59, 1258\u20131263 (2020).","journal-title":"Int. J. Dermatol."},{"key":"879_CR45","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.ejca.2013.03.010","volume":"49","author":"SC Flohil","year":"2013","unstructured":"Flohil, S. C., van der Leest, R. J., Arends, L. R., de Vries, E. & Nijsten, T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur. J. Cancer 49, 2365\u20132375 (2013).","journal-title":"Eur. J. Cancer"},{"key":"879_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0190-9622(93)70003-C","volume":"28","author":"A Marghoob","year":"1993","unstructured":"Marghoob, A. et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J. Am. Acad. Dermatol. 28, 22\u201328 (1993).","journal-title":"J. Am. Acad. Dermatol."},{"key":"879_CR47","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ccell.2020.12.022","volume":"39","author":"E Ramelyte","year":"2021","unstructured":"Ramelyte, E. et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell 39, 394\u2013406.e4 (2021).","journal-title":"Cancer Cell"},{"key":"879_CR48","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-023-02309-4","volume":"29","author":"H Soliman","year":"2023","unstructured":"Soliman, H. et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat. Med. 29, 450\u2013457 (2023).","journal-title":"Nat. Med."},{"key":"879_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00881-3","volume":"13","author":"F Zhang","year":"2021","unstructured":"Zhang, F. et al. IFN-\u03b3 and TNF-\u03b1 drive a CXCL10+CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. Genome Med. 13, 64 (2021).","journal-title":"Genome Med"},{"key":"879_CR50","doi-asserted-by":"publisher","first-page":"1109991","DOI":"10.3389\/fgene.2023.1109991","volume":"14","author":"W Yao","year":"2023","unstructured":"Yao, W. et al. C1QC is a prognostic biomarker with immune-related value in kidney renal clear cell carcinoma. Front. Genet. 14, 1109991 (2023).","journal-title":"Front. Genet."},{"key":"879_CR51","doi-asserted-by":"publisher","first-page":"911368","DOI":"10.3389\/fimmu.2023.911368","volume":"14","author":"J Tu","year":"2023","unstructured":"Tu, J., Wang, D., Zheng, X. & Liu, B. Single-cell RNA datasets and bulk RNA datasets analysis demonstrated C1Q+ tumor-associated macrophage as a major and antitumor immune cell population in osteosarcoma. Front. Immunol. 14, 911368 (2023).","journal-title":"Front. Immunol."},{"key":"879_CR52","doi-asserted-by":"crossref","unstructured":"Wu, J., Shen, Y., Zeng, G., Liang, Y. & Liao, G. SPP1+ TAM subpopulations in tumor microenvironment promote intravasation and metastasis of head and neck squamous cell carcinoma. Cancer Gene Ther. 31, 311\u2013321 (2024).","DOI":"10.1038\/s41417-023-00704-0"},{"key":"879_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coi.2021.09.005","volume":"74","author":"L Poncette","year":"2022","unstructured":"Poncette, L., Bluhm, J. & Blankenstein, T. The role of CD4 T cells in rejection of solid tumors. Curr. Opin. Immunol. 74, 18\u201324 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"879_CR54","doi-asserted-by":"publisher","first-page":"1591875","DOI":"10.1080\/2162402X.2019.1591875","volume":"8","author":"PK Bommareddy","year":"2019","unstructured":"Bommareddy, P. K., Zloza, A., Rabkin, S. D. & Kaufman, H. L. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology 8, 1591875 (2019).","journal-title":"Oncoimmunology"},{"key":"879_CR55","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/CMR.0000000000000824","volume":"32","author":"E Mulder","year":"2022","unstructured":"Mulder, E. et al. Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma. Melanoma Res. 32, 249\u2013259 (2022).","journal-title":"Melanoma Res."},{"key":"879_CR56","doi-asserted-by":"publisher","first-page":"678127","DOI":"10.3389\/fcell.2021.678127","volume":"9","author":"GS Kinker","year":"2021","unstructured":"Kinker, G. S. et al. B cell orchestration of anti-tumor immune responses: a matter of cell localization and communication. Front. Cell Dev. Biol. 9, 678127 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"879_CR57","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1158\/2326-6066.CIR-17-0075","volume":"5","author":"TC Bruno","year":"2017","unstructured":"Bruno, T. C. et al. Antigen-presenting intratumoral B cells affect CD4+ TIL phenotypes in non-small cell lung cancer patients. Cancer Immunol. Res. 5, 898\u2013907 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"879_CR58","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"879_CR59","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"879_CR60","unstructured":"WHO Handbook for Reporting Results of Cancer Treatment WHO Offset Publication No. 48 (World Health Organization, 1979)."},{"key":"879_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12160-2","volume":"10","author":"J Griss","year":"2019","unstructured":"Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).","journal-title":"Nat. Commun."},{"key":"879_CR62","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"879_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giaa151","volume":"9","author":"MD Young","year":"2020","unstructured":"Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. Gigascience 9, giaa151 (2020).","journal-title":"Gigascience"},{"key":"879_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"879_CR65","doi-asserted-by":"publisher","first-page":"eabl4896","DOI":"10.1126\/science.abl4896","volume":"376","author":"RC Jones","year":"2022","unstructured":"Jones, R. C. et al. The Tabula Sapiens: a multiple-organ, single-cell transcriptomic atlas of humans. Science 376, eabl4896 (2022).","journal-title":"Science"},{"key":"879_CR66","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e21 (2019).","journal-title":"Cell"},{"key":"879_CR67","doi-asserted-by":"publisher","unstructured":"Christoph Hafemeister, F. H. Single-cell RNA-seq differential expression tests within a sample should use pseudo-bulk data of pseudo-replicates. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.03.28.534443 (2023).","DOI":"10.1101\/2023.03.28.534443"},{"key":"879_CR68","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16, 284\u2013287 (2012).","journal-title":"Omics"},{"key":"879_CR69","doi-asserted-by":"crossref","unstructured":"Dolgalev, I. MSigDB gene sets for multiple organisms in a tidy data format. GitHub https:\/\/igordot.github.io\/msigdbr\/ (2022).","DOI":"10.32614\/CRAN.package.babelgene"},{"key":"879_CR70","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3389\/fphar.2019.00445","volume":"10","author":"R Huang","year":"2019","unstructured":"Huang, R. et al. The NCATS BioPlanet: an integrated platform for exploring the universe of cellular signaling pathways for toxicology, systems biology, and chemical genomics. Front. Pharmacol. 10, 445 (2019).","journal-title":"Front. Pharmacol."},{"key":"879_CR71","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. B Methodol."},{"key":"879_CR72","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"879_CR73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Res. 9, 47 (2020).","journal-title":"F1000Res."},{"key":"879_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14273-0","volume":"11","author":"A Reuben","year":"2020","unstructured":"Reuben, A. et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat. Commun. 11, 603 (2020).","journal-title":"Nat. Commun."},{"key":"879_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control Clin. Trials"},{"key":"879_CR76","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332 (2010).","journal-title":"BMJ"},{"key":"879_CR77","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00879-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T18:04:21Z","timestamp":1738173861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00879-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00879-x","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.R. received speaker honoraria from Bristol-Myers Squibb, Roche, Amgen and Novartis and travel support by Sanofi, Roche and Bristol-Myers Squibb through the institution. P.T. received honoraria from Silverchair, unrestricted grants for education projects from Lilly, and honoraria for lectures from AbbVie, Lilly, FotoFinder and Novartis. J.T. reports an unrestricted grant from Lilly, consulting fees from Lilly, speaker honoraria from Lilly and Novartis, all outside the submitted work, as well as travel support from Almirall, AbbVie and Bristol-Myers Squibb through institution. C.H. reports speaker honoraria from Amgen, BMS, MSD, Novartis, Roche, participation in advisory Boards: Amgen, Astra Zeneca, BMS, Incyte, MSD, Novartis, Pierre Fabre, Roche and research funding by Amgen to the institution. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}